+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ZL-1310 compared to the Investigators Choice Therapy in participants with relapsed small cell lung cancer SCLC. This phase 3 study aims to understand how well ZL-1310, a DLL3 antibody-drug conjugate, works against SCLC that has returned after initial treatment, with a focus on response rates and overall survival. Participants will receive either ZL-1310 as a single drug or Investigators Choice Therapy, which includes options like Topotecan or Amrubicin. The study is randomized and open-label, meaning participants are assigned to one of these treatments without masking. Treatment effects will be monitored over up to 30 months, with evaluations conducted regularly throughout this period. During the trial, participants will undergo tumor biopsies or provide archived tumor tissue samples at screening. They will be assessed for measurable disease and monitored for response using standard criteria RECIST v1.1, as well as quality of life measures. Safety will be tracked by recording treatment-related side effects and adverse events. The study includes comprehensive evaluations of survival, response duration, progression-free survival, and central nervous system responses, with participation lasting up to nearly three years.

Age: 18Years +All GendersPhase 3
165 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Hetrombopag Olamine Tablets compared to a placebo in patients with thrombocytopenia caused by chemotherapy. The study focuses on patients who have solid tumors and experience low platelet counts due to chemotherapy treatment. This phase III trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and aims to better understand treatment options for chemotherapy-induced thrombocytopenia. Participants receive treatments in two parts in Part A, all participants are given Hetrombopag Olamine. In Part B, participants are randomly assigned to receive either Hetrombopag Olamine or a matching placebo. Treatments are given during chemotherapy cycles that occur every 14 or 21 days. The study includes monitoring over approximately 3 years to assess platelet counts and the need for rescue therapies. During the study, participants undergo regular monitoring of platelet levels, safety labs, and vital signs. Researchers track whether participants maintain platelet counts sufficient to continue chemotherapy without delay or modification. Outcomes include measuring platelet count improvements, bleeding events, and adverse reactions. The overall participation lasts up to about three years, with ongoing assessment of chemotherapy cycle completion and treatment safety.

Age: 18Years +All GendersPhase 3
51 locations
S

Actively Recruiting

Researchers are exploring new treatment options for people with advanced colorectal cancer that has spread or cannot be removed by surgery. This cancer type, affecting the colon or rectum, sometimes involves problems with the bodys DNA repair system called dMMR or a condition called MSI. These issues can cause cancer cells to rely on a protein called Werner helicase to survive. Blocking this protein might help stop cancer growth with less harm to healthy cells. This Phase 2 study evaluates a drug named VVD-133214 that blocks Werner helicase, combined with pembrolizumab, an immunotherapy drug approved to help the immune system attack cancer cells. Participants in this trial will receive oral VVD-133214 along with pembrolizumab given by intravenous infusion every three weeks. The study compares this combination to pembrolizumab alone to find the best dose of VVD-133214 and to assess whether the combination works better. Participants will receive VVD-133214 as long as it remains helpful without causing serious side effects, while pembrolizumab treatment will continue for up to two years. Participants may stop treatment at any time. During the trial, participants will have regular visits for tests, scans, and health check-ups to monitor how their cancer responds and to track any new or worsening medical problems. After stopping treatment, follow-up visits will occur 30 days after the last VVD-133214 dose and 100 days after the last pembrolizumab dose. Long-term follow-up visits will continue every 90 days as long as participants agree to remain in the study. The main outcome measured is the progression-free survival rate at six months, with safety and other response measures also monitored throughout up to about 36 months.

Age: 18Years +All GendersPhase 2
122 locations
E

Actively Recruiting

Researchers are evaluating treatments for people with advanced non-small cell lung cancer NSCLC that has spread or cannot be controlled by current therapies. This study focuses on patients whose cancer cells have specific changes called HER2 mutations, which cause abnormal cell growth. The main goal is to compare the effectiveness and safety of a new drug called sevabertinib against the standard treatment for this condition. Participants will be randomly assigned to one of two groups one group will take sevabertinib tablets twice daily, and the other will receive the current standard treatment, which includes pembrolizumab combined with platinum-based chemotherapy given by vein infusion every 21 days. Those on standard treatment may switch to sevabertinib if their cancer worsens. Treatment continues as long as participants benefit and do not have severe side effects. During the study, participants will undergo scans like CT, PET, MRI, or X-rays to monitor their cancer. Health assessments include blood and urine tests, heart checks using electrocardiograms and echocardiograms, pregnancy tests when needed, and evaluations of how participants feel and any medical problems they experience. The main outcome measured is how long participants live without their cancer progressing, with other outcomes including overall survival and response rates. The study lasts up to about 4 years, with ongoing monitoring for safety and patient well-being.

Age: 18Years +All GendersPhase 3
279 locations
C

Actively Recruiting

The trial investigates the effectiveness of two different Schroth exercise approaches in adolescents aged 10 to 18 years with Adolescent Idiopathic Scoliosis AIS, a condition causing a three-dimensional spinal curvature. AIS affects a small percentage of children and, if untreated, curves between 10 and 45 may worsen, leading to pain, breathing issues, posture problems, and lower quality of life. Traditional treatments like bracing and surgery have limitations, so physiotherapeutic scoliosis-specific exercises, especially the Schroth method, are being evaluated as a conservative first treatment option. Participants are randomly assigned to one of two groups one receives supervised Schroth exercises guided one-on-one by a physiotherapist, and the other follows the same Schroth exercise program at home with initial instruction and an individualized booklet. Both involve 60-minute sessions, 5 days per week, over 12 weeks, focusing on specific techniques such as 3D auto-correction, rotational breathing, and curve-specific exercises. During the study, participants complete assessments of spinal curvature and posture, respiratory function through spirometry, pain levels, and quality of life at the start and after the intervention period. Researchers measure changes in the Cobb angle and other spinal parameters to compare treatment effects. Participants and their families provide consent and cooperate with all study-related activities. The study is expected to finish by August 2027.

Age: 10Years - 18YearsAll GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are evaluating whether combining the investigational drug mevrometostat PF-06821497 with enzalutamide works better than enzalutamide alone in men with metastatic castration-sensitive prostate cancer mCSPC who have not received androgen receptor pathway inhibitors or chemotherapy for mCSPC. This Phase 3, global, multicenter, randomized, double-blind, placebo-controlled study focuses on participants with prior limited androgen-deprivation therapy and no disease progression or rising PSA before treatment starts. Participants are randomly assigned to one of two groups one receives mevrometostat 875 mg twice daily plus enzalutamide 160 mg once daily, and the other receives a placebo plus enzalutamide at the same dose. The study includes a screening phase, treatment phase, safety follow-up, and long-term follow-up. Treatment is oral and taken continuously during the trial. During the study, participants undergo various assessments including imaging scans to track disease progression, laboratory tests, and patient-reported questionnaires on pain, quality of life, and fatigue. Researchers will monitor radiographic progression-free survival for up to about 4 years and overall survival for up to about 9 years. Safety and pharmacokinetics of mevrometostat combined with enzalutamide are also evaluated. The total duration includes screening, treatment, safety monitoring, and extended follow-up phases.

Age: 18Years +MALEPhase 3
319 locations